Drug for ameliorating chronic atrophic gastritis and use thereof

By developing 9,13-substituted berberine derivatives, the treatment challenges of chronic atrophic gastritis have been solved, achieving significant improvement in gastric mucosa and inhibition of inflammatory factors, thus providing a more effective treatment option.

WO2026233445A1PCT designated stage Publication Date: 2026-11-12INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095854
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-09
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing treatments for chronic atrophic gastritis are insufficient to completely cure the atrophy and intestinal metaplasia of the gastric mucosa, and different patients respond to treatment in great ways, with long-term medication potentially causing side effects.

Method used

A 9,13-substituted berberine derivative is provided, which is prepared into a pharmaceutical composition for the treatment of chronic atrophic gastritis by inhibiting the expression of inflammatory factors and improving the state of the gastric mucosa.

Benefits of technology

It significantly improves the atrophy of gastric mucosal glandular epithelial cells and the expression of inflammatory factors, alleviates the symptoms of chronic atrophic gastritis, is superior to traditional drugs such as Berberine, and has no obvious side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095854_12112026_PF_FP_ABST
    Figure CN2026095854_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of small molecule drugs, and specifically relates to a drug for ameliorating chronic atrophic gastritis and the use thereof. An objective of the present application is to provide a compound, a pharmaceutical composition containing the compound and the use thereof. The 9,13-substituted berberine derivative of the present application has a good ameliorative effect on CAG. Further studies are performed to observe the inhibitory effects of the compound on the atrophy of gastric mucosal glandular epithelial cells, thinning of the gastric mucosa, extensive neutrophil and lymphocyte infiltration and adhesion, inflammatory factors, etc. in CAG, and it is found that the 9,13-substituted berberine derivative of the present application can be used for preventing and / or treating CAG.
Need to check novelty before this filing date? Find Prior Art

Description

A drug for improving chronic atrophic gastritis and its application.

[0001] Cross-referencing

[0002] This application claims priority to Chinese Patent Application No. 202510593064.5, filed on May 9, 2025, entitled “A drug for improving chronic atrophic gastritis and its application thereto,” the entire disclosure of which is incorporated herein by reference. Technical Field

[0003] This application relates to the field of small molecule drug technology, specifically to a drug for improving chronic atrophic gastritis and its application. Background Technology

[0004] Chronic atrophic gastritis (CAG) is a chronic digestive system disease caused by multiple pathogenic factors. Long-term chronic inflammation leads to atrophy of the gastric mucosal glands (reduced number and function), resulting in decreased gastric secretion of gastric juice and pepsin, thus affecting the normal physiological function of the stomach. Most patients experience varying degrees of abdominal pain, poor appetite, and belching. It is characterized by a long and difficult-to-cure course, significantly impacting patients' quality of life. CAG is classified as a precancerous condition of the stomach by the World Health Organization, especially for patients with intestinal metaplasia and dysplasia, whose risk of cancer is even higher. Timely and effective treatment is crucial.

[0005] Helicobacter pylori infection is one of the most important causes of chronic atrophic gastritis (CAG), with almost all currently infected individuals also having chronic active gastritis. It is also a major contributing factor to peptic ulcers, dyspepsia, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Dietary and environmental factors are related to the occurrence of CAG. Poor dietary habits such as consuming excessively cold, hot, rough, or irritating foods can lead to damage to the gastric mucosa. Epidemiological studies show that high salt intake and a lack of fresh fruits and vegetables are closely related to gastric mucosal atrophy, intestinal metaplasia, and the development of gastric cancer. Autoimmune gastritis is a type of CAG caused by an autoimmune mechanism. Patients produce autoantibodies against different components of gastric tissue, such as anti-intrinsic factor antibodies and anti-parietal cell antibodies, resulting in tissue damage and functional impairment. It may be accompanied by other autoimmune diseases, such as thyroid disease and type 1 diabetes. Bile reflux is also a common cause of chronic atrophic gastritis. The surface of a normal gastric mucosa is covered by a mucus-bicarbonate barrier, which prevents gastric acid from penetrating into the mucosa. Gastrointestinal motility abnormalities, liver and biliary tract diseases, and distal gastrointestinal obstruction caused by various reasons can lead to bile reflux. The refluxed bile, pancreatic juice, and duodenal fluid can damage the gastric mucosal barrier, causing gastric mucosal injury. Long-term, repeated irritation can develop into chronic atrophic gastritis (CAG). Drug factors, especially nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, can directly damage the gastric mucosa; they can also inhibit prostaglandin synthesis through metabolic pathways, reducing the gastric mucosa's defense and repair capabilities, which is also a clear pathogenic factor for CAG. Alcohol consumption can also cause gastric mucosal injury and bleeding. The combined use of alcohol and NSAIDs can cause even more severe damage to the gastric mucosa. Furthermore, the mucosa of the elderly may undergo degenerative changes, reducing the gastric mucosal repair and regeneration function, and causing glandular atrophy in the epithelium. Therefore, CAG is more common in the elderly population.

[0006] Currently, treatment for CAG primarily focuses on relieving symptoms, improving gastric mucosal condition, and preventing cancerous changes. For CAG infected with Helicobacter pylori (Hp), eradicating Hp is key to treatment, as it can slow down or reverse the atrophy and intestinal metaplasia of the gastric mucosa. The use of antacids, gastric mucosal protectants, and prokinetic drugs can effectively relieve symptoms such as bloating, abdominal pain, and indigestion. Traditional Chinese medicine treatment has shown some effectiveness in improving symptoms and gastric mucosal condition. For example, traditional Chinese medicine preparations such as Moluodan and Weifuchun, through mechanisms such as promoting blood circulation, removing blood stasis, and strengthening the spleen and stomach, help repair the gastric mucosa. Improving dietary habits and lifestyle, such as reducing the intake of spicy and irritating foods, quitting smoking and limiting alcohol consumption, and maintaining a regular sleep schedule, has a positive effect on improving the patient's overall health and symptoms.

[0007] However, current treatments for chronic atrophic gastritis (CAG) still have some limitations. While treatment can effectively relieve symptoms, it often cannot completely cure CAG, especially the atrophy and intestinal metaplasia of the gastric mucosa. Furthermore, different patients may respond significantly to treatment, which can affect the prediction and adjustment of treatment outcomes. Long-term use of certain medications may cause side effects, such as damage to the gastric mucosa from long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). Long-term maintenance therapy is necessary, but some patients may discontinue medication on their own due to side effects or symptom relief, affecting treatment effectiveness. In conclusion, the treatment of CAG is a comprehensive process that requires individualized treatment plans based on the patient's specific situation. While current treatments can alleviate symptoms and improve the condition of the gastric mucosa to some extent, achieving a complete cure remains a challenge.

[0008] Application content

[0009] This application aims to at least partially solve one of the technical problems in the related art. To this end, one object of this application is to provide a compound, a pharmaceutical composition comprising said compound, and its use. The 9,13-substituted berberine derivative of general formula (I) of this application has a good ameliorative effect on CAG. Further research and observation of the compound's inhibitory effects on gastric mucosal glandular epithelial cell atrophy, gastric mucosal thinning, large-scale neutrophil and lymphocyte infiltration and adhesion, inflammatory factors, etc., in CAG have revealed that the 9,13-substituted berberine derivative of this application can be used for the prevention and / or treatment of CAG.

[0010] Therefore, the first aspect of this application provides a compound, said compound being a compound of general formula (I) or a stereoisomer, tautomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug of a compound of general formula (I):

[0011] R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl;

[0012] m = 1 ~ 10, n = 1 ~ 10,

[0013] R3 is a 3-10 membered heterocyclic group, C6-C20 aryl group, or 5-20 membered heteroaryl group that is unsubstituted or substituted with at least one Rb.

[0014] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C20 alkoxy, C1-C20 alkyl, C2-C20 alkenyl, and C2-C20 alkynyl.

[0015] The applicant improved the structure of berberine to obtain the 9,13-substituted berberine derivative shown in general formula (I) of this application, and unexpectedly discovered that the compound has an inhibitory effect on gastric mucosal glandular epithelial cell atrophy, gastric mucosal thinning, large number of neutrophil and lymphocyte infiltration and adhesion, inflammatory factors, etc. of CAG. Therefore, the 9,13-substituted berberine derivative of this application can be used for the prevention and / or treatment of CAG, and can be used to prepare drugs for the treatment of CAG.

[0016] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0017] m = 1 ~ 10, n = 1 ~ 10,

[0018] R3 is an unsubstituted or substituted C6-C20 aryl or 5-20 heteroaryl group with at least one Rb substitution;

[0019] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C15 alkoxy, C1-C15 alkyl, C2-C15 alkenyl, and C2-C15 alkynyl.

[0020] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0021] m = 1~5, n = 1~10

[0022] R3 is an unsubstituted or C6-C20 aryl group substituted with at least one Rb;

[0023] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0024] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl;

[0025] m = 1~5, n = 1~10

[0026] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0027] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0028] According to embodiments of this application, Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, and C1-C10 alkyl.

[0029] According to an embodiment of this application, Ra is -NH2;

[0030] Rb is selected from -NO2, halogens, C1-C10 alkoxy groups, and C1-C10 alkyl groups.

[0031] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted C2-C10 alkenyl, unsubstituted C2-C10 alkynyl, unsubstituted or substituted with at least one Ra alkyl group.

[0032] m = 1~5, n = 1~10

[0033] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0034] Ra is -NH2;

[0035] Rb is selected from -NO2, halogens, C1-C10 alkoxy groups, and C1-C10 alkyl groups.

[0036] According to embodiments of this application, the compound is selected from one of the following structures:

[0037] A second aspect of this application provides a pharmaceutical composition. According to embodiments of this application, the pharmaceutical composition comprises the compound described in the first aspect.

[0038] According to embodiments of this application, the pharmaceutical composition further includes pharmaceutically acceptable excipients, such as pharmaceutically acceptable carriers, diluents, or excipients.

[0039] The compounds provided in this application are used to prepare drugs in various dosage forms, which are then administered to subjects at therapeutically effective amounts. After being absorbed by the subjects, the drugs can treat or improve chronic atrophic gastritis.

[0040] According to embodiments of this application, the pharmaceutical composition further comprises one or more other therapeutic agents. These other therapeutic agents function similarly to the compounds of this application and can all be used to treat or improve chronic atrophic gastritis.

[0041] This application relates to suitable pharmaceutically acceptable salts of compounds of general formula (I) or (I), including but not limited to hydrochlorides, hydrobromicates, sulfates or hydrogen sulfates, phosphates or hydrogen phosphates, acetates, benzoates, succinates, fumarates, maleates, lactates, citrates, tartrates, gluconates, methanesulfonates, benzenesulfonates, or p-toluenesulfonates. As stated above, any compound of this application mentioned herein includes its pharmaceutically acceptable salt, solvate, or combination thereof.

[0042] In addition to pharmaceutically acceptable salts of the compounds of this application, this application also includes other salts. These may serve as intermediates in the purification of the compounds or in the preparation of other pharmaceutically acceptable salts, or may be used for the identification, characterization, or purification of the compounds of this application.

[0043] The third aspect of this application provides the use of the compound described in the first aspect in the preparation of a medicament for treating chronic atrophic gastritis.

[0044] The applicant demonstrated the inhibitory and therapeutic effects of the 9,13-substituted berberine derivative of this application on CAG through a series of in vitro and in vivo experiments. Specifically, the applicant found that the 9,13-substituted berberine derivative provided in this application can alleviate the development of CAG in mice by inhibiting the expression of inflammatory factors; its therapeutic effect on mouse CAG is superior to that of berberine; the applicant found that the berberine derivative of this application treats mouse CAG by improving the degree of gastric mucosal lesions at the pathological level and inhibiting the expression of inflammatory factors at the cellular and protein levels. In summary, the applicant has discovered a compound of general formula (I) that can improve and treat CAG and can be used to prepare a drug for treating CAG.

[0045] Additional aspects and advantages of this application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of this application. Attached Figure Description

[0046] The above and / or additional aspects and advantages of this application will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which:

[0047] Figure 1 shows the effect of BBR and the berberine derivative of this application on the IL-1β content in the supernatant of MNNG-induced GES-1 cells;

[0048] Figure 2 shows the effects of BBR and the berberine derivative of this application on the viability of GES-1 cells;

[0049] Figure 3 shows the effects of BBR and the berberine derivative of this application on the gastric mucosa of CAG model mice;

[0050] Figure 4 shows the HE staining results of the gastric mucosa of mice in the normal group, CAG group, BBR group and BBR-5 group;

[0051] Figure 5 shows the IHC detection results of the gastric mucosa of mice in the normal group, CAG group, BBR group and BBR-5 group;

[0052] Figure 6 shows the protein expression of inflammatory mediators TNF-α, IL-6, and IL-1β in the gastric tissues of mice in the normal group, CAG group, BBR group, and BBR-5 group. Detailed Implementation

[0053] The embodiments of this application are described in detail below. The embodiments described below are exemplary and are only used to explain this application, and should not be construed as limiting this application.

[0054] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this application, unless otherwise stated, "multiple" means two or more.

[0055] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0056] To facilitate understanding of this application, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this application pertains.

[0057] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this application but do not exclude other contents.

[0058] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.

[0059] Terminology Definitions and Explanations

[0060] Unless otherwise stated, the definitions of groups and terms recorded in this application specification and claims, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and definitions of specific compounds in the examples, can be arbitrarily combined and combined with each other. Such combinations and combinations of group definitions and compound structures shall fall within the scope of this application specification.

[0061] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable, non-toxic salt of an acid or base, including salts of inorganic acids and bases, and salts of organic acids and bases. Salts derived from inorganic bases include, but are not limited to, metal salts formed from Al, Ca, Li, Mg, K, Na, and Zn; salts derived from organic bases include, but are not limited to, salts of primary, secondary, or tertiary amines, including naturally occurring substituted or unsubstituted amines, cyclic amines, and basic ion exchange resins such as ammonium, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, caffeine, procaine, choline, betaine, penicillin, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, or polyamine resins. Organic salts derived from inorganic and organic acids, including but not limited to those formed from sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, hydrochloric acid, formic acid, acetic acid, propionic acid, benzenesulfonic acid, benzoic acid, phenylacetic acid, salicylic acid, alginic acid, aminoanilic acid, camphoric acid, citric acid, vinyl sulfonic acid, formic acid, fumaric acid, furoic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, mucilage, dihydroxynaphthyl acid, pantothenic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, malonic acid, 2-hydroxypropionic acid, oxalic acid, glycolic acid, galacturonic acid, citric acid, lysine, arginine, aspartic acid, cinnamic acid, methanesulfonic acid, ethanesulfonic acid, or trifluoromethanesulfonic acid.

[0062] The term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformational isomers.

[0063] The term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions within a molecule. The compounds in this application exhibit tautomerism. Tautomers can exist in two or more interconvertible forms. Proton-shift tautomers arise from the migration of covalently bonded hydrogen atoms between two atoms. Tautomers generally exist in equilibrium; attempts to isolate a single tautomer typically yield a mixture whose physicochemical properties are consistent with those of the mixture of compounds. The equilibrium position depends on the intramolecular chemical characteristics. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the ketone form is dominant; while in phenols, the enol form is dominant. This application encompasses all tautomeric forms of the compounds.

[0064] The term "drug" refers to one or more compounds described in this application or their physiologically / pharmaceutical-acceptable salts or prodrugs mixed with other chemical components, such as physiologically / pharmaceutical-acceptable carriers and excipients. The purpose of a drug is to facilitate the administration of the compound to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0065] The term "solvent" refers to a compound or salt thereof of this application comprising a stoichiometric or nonstoichiometric solvent bound by intermolecular noncovalent forces, and a hydrate when the solvent is water.

[0066] The term "prodrug" refers to a compound of this application that can be converted into a biologically active form under physiological conditions or through solvation. The prodrug of this application is prepared by modifying a functional group in the compound; this modification can be performed conventionally or removed in vivo to obtain the parent compound.

[0067] The term “C1-C10 alkyl” should be understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. The alkyl group is, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, etc.; "C1-C6 alkyl" should be understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms.

[0068] The term “C2-C20 alkynyl” should be understood to preferably represent a straight-chain or branched monovalent hydrocarbon group containing one or more triple bonds and having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.

[0069] The term “C2-C20 alkenyl” should be understood to preferably represent a straight-chain or branched monovalent hydrocarbon group containing one or more double bonds and having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.

[0070] The term "3-10 membered heterocyclic group" refers to a saturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1-5, preferably 1-3, heteroatoms selected from N, O, and S. Specifically, the heterocyclic group may include, but is not limited to: 4-membered rings, such as azirmonobutylene and oxobutylene; 5-membered rings, such as tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoalkyl, pyrazolyl, or pyrrololinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazinyl, or trithiaalkyl; or 7-membered rings, such as diazacycloheptyl. Optionally, the heterocyclic group may be benzofused. The heterocyclic group may be bicyclic, such as, but not limited to, a 5,5-membered ring, like a hexahydrocyclopentano[c]pyrrole-2(1H)-yl ring, or a 5,6-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring. The nitrogen-containing ring may be partially unsaturated, i.e., it may contain one or more double bonds, such as, but not limited to, 2,5-dihydro-1H-pyrrole, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl, or it may be benzofused, such as, but not limited to, dihydroisoquinolinyl. According to this application, the heterocyclic group is non-aromatic.

[0071] The term "C6-C20 aryl" should be understood to preferably refer to a monocyclic, bicyclic, or tricyclic hydrocarbon ring having 6-20 carbon atoms and exhibiting monovalent aromatic or partially aromatic properties. In particular, it refers to a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring having 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring having 10 carbon atoms ("C10 aryl"), such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl; or a ring having 13 carbon atoms ("C13 aryl"), such as fluorenyl; or a ring having 14 carbon atoms ("C14 aryl"), such as anthraceneyl.

[0072] The term "5-20-membered heteroaryl" should be understood to include monovalent monocyclic, bicyclic, or tricyclic aromatic ring systems having 5-20 ring atoms and containing 1-5 heteroatoms independently selected from N, O, and S, such as "5-14-membered heteroaryl". The term "5-14-membered heteroaryl" should also be understood to include monovalent monocyclic, bicyclic, or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ring atoms, particularly 5, 6, 9, or 10 carbon atoms, and containing 1-5, preferably 1-3, heteroatoms each independently selected from N, O, and S, and in each case, may be benzofused. Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazoleyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl, and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzooxazolyl, benzoisooxazolyl, benzoimidazolyl, benzotriazolyl, indazole, indolyl, isindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and their benzo[derivatives], such as quinolinyl, quinazolinyl, isoquinolinyl, etc.; or acrylinyl, inazinyl, purinyl, and their benzo[derivatives]; or terpenolyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphridinyl, pteridinyl, carbazolyl, acridineyl, phenazinyl, phenothiazinyl, phenothiazinyl, etc.

[0073] The term "excipient" refers to a pharmaceutically acceptable inert ingredient. Non-limiting examples of the types of "excipients" include binders, disintegrants, lubricants, flow aids, stabilizers, fillers, and diluents. Excipients enhance the handling properties of pharmaceutical formulations by increasing flowability and / or adhesion, making the formulation more suitable for direct compression. Typical examples of pharmaceutically acceptable carriers suitable for the above formulations include: sugars, such as lactose, sucrose, mannitol, and sorbitol, or corn starch, tapioca starch, and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; calcium phosphates, such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone; polyvinyl alcohol; stearic acid; alkaline earth metal stearates, such as magnesium stearate and calcium stearate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; nonionic, cationic, and anionic surfactants; ethylene glycol polymers; fatty alcohols; and hydrolyzed cereal solids and other nontoxic, compatible excipients commonly used in pharmaceutical formulations, such as fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, and colorants.

[0074] Natural products provide a variety of lead structures and novel drugs for the discovery and development of contemporary drugs. Derivatives of natural products are considered privileged molecular entities in drug discovery activities, highlighting new potential therapeutic efficacies beyond their original biological space. This application relates to a derivative of berberine, which, through structural modification, exhibits significantly superior activity compared to berberine itself. This derivative can alleviate and treat MNNG-induced CAG, improve inflammatory cytokines, and has no side effects on liver and kidney function. Analytical results show that the derivative has a very significant therapeutic effect on mouse-level CAG, indicating that berberine derivatives may be potential drugs for treating CAG. This study provides new research ideas for elucidating the role of berberine derivatives in improving CAG.

[0075] Chronic gastritis includes chronic superficial gastritis and chronic atrophic gastritis (CAG). Atrophic gastritis is considered a breeding ground for cancer and is listed by the World Health Organization as one of the precancerous conditions of gastric cancer. In recent years, due to the widespread use of gastroscopy, the detection rate of chronic superficial gastritis and CAG has been on the rise. The etiology of CAG is complex and is related to genetic factors, metal exposure, bile or duodenal fluid reflux, immune factors, and Helicobacter pylori infection. Pathologically, it is characterized by varying degrees of glandular atrophy and disappearance, replaced by pyloric gland metaplasia or intestinal metaplasia, with significant interstitial inflammatory infiltration.

[0076] CAG (Chronic Atrophic Glandular Syndrome) is a chronic gastric disease characterized by atrophy, reduction, or disappearance of gastric mucosal glands, often accompanied by mucosal thinning, intestinal metaplasia, or dysplasia. While more common in middle-aged and elderly individuals, its incidence has been increasing in younger populations in recent years, closely related to factors such as Helicobacter pylori (Hp) infection and unhealthy lifestyle habits. CAG is a precancerous lesion of gastric cancer, especially when combined with intestinal metaplasia or dysplasia, significantly increasing the risk of malignant transformation; therefore, early diagnosis and treatment are crucial.

[0077] There is currently no particularly effective treatment for chronic atrophic gastritis. Symptomatic treatment primarily focuses on managing symptoms, and it is generally difficult to reverse the atrophic condition. Western medicine treatment mainly aims to eliminate the underlying cause, selecting commonly used medications based on the patient's condition, avoiding drugs that damage the gastric mucosa such as corticosteroids, and actively treating related diseases and infections.

[0078] Berberine, also known as berberine alkaloid, is a common isoquinoline alkaloid. Modern pharmacological studies have shown that berberine possesses various biological activities, including anti-inflammatory effects. Berberine inhibits inflammatory responses through multiple mechanisms, exhibiting significant anti-inflammatory effects. Berberine can enhance human immunity and regulate immune system function, making it indispensable for addressing certain autoimmune and related health problems. This application describes a novel small-molecule drug derivative synthesized by rationally modifying and altering the molecular structure of berberine. Combining the superior anti-inflammatory activity of berberine itself, this study aims to verify whether the berberine derivative has a better effect on improving chronic atrophic angina (CAG) and whether it can be rationally developed and applied as a potential drug for the treatment of CAG, providing more options for clinical medication of CAG.

[0079] Therefore, the purpose of this application is to provide a class of 9,13-substituted berberine derivatives, their preparation methods, and applications. Through the rational design and modification of BBR, candidate drugs with improved activity, novel mechanisms, and good safety are obtained.

[0080] According to a specific embodiment of this application, this application provides a compound, said compound being a compound of general formula (I) or a stereoisomer, tautomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug of a compound of general formula (I):

[0081] R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl;

[0082] m = 1 ~ 10, n = 1 ~ 10,

[0083] R3 is a 3-10 membered heterocyclic group, C6-C20 aryl group, or 5-20 membered heteroaryl group that is unsubstituted or substituted with at least one Rb.

[0084] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C20 alkoxy, C1-C20 alkyl, C2-C20 alkenyl, and C2-C20 alkynyl.

[0085] It should be noted that m can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10; n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. For example, m can be 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 or 1-10, and n can be 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 or 1-10.

[0086] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0087] m = 1 ~ 10, n = 1 ~ 10,

[0088] R3 is an unsubstituted or substituted C6-C20 aryl or 5-20 heteroaryl group with at least one Rb substitution;

[0089] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C15 alkoxy, C1-C15 alkyl, C2-C15 alkenyl, and C2-C15 alkynyl.

[0090] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0091] m = 1~5, n = 1~10

[0092] R3 is an unsubstituted or C6-C20 aryl group substituted with at least one Rb;

[0093] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0094] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl;

[0095] m = 1~5, n = 1~10

[0096] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0097] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0098] According to a specific embodiment of this application, Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, and C1-C10 alkyl.

[0099] According to a specific embodiment of this application, Ra is -NH2;

[0100] Rb is selected from -NO2, halogens, C1-C10 alkoxy groups, and C1-C10 alkyl groups.

[0101] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted C2-C10 alkenyl, unsubstituted C2-C10 alkynyl, unsubstituted or substituted with at least one Ra alkyl group.

[0102] m = 1~5, n = 1~10

[0103] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0104] Ra is -NH2;

[0105] Rb is selected from -NO2, halogens, C1-C10 alkoxy groups, and C1-C10 alkyl groups. Among them, halogens are fluorine, chlorine, bromine, and iodine.

[0106] According to a specific embodiment of this application, this application provides a method for preparing a 9,13-substituted berberine derivative, comprising the following steps:

[0107] (S-1), anhydrous acetonitrile, potassium carbonate, and the first raw material were reacted at 60–70 °C. The reaction progress was monitored by TLC. After the reaction was complete, the mixture was cooled until the solid completely precipitated. The mixture was filtered, and the filtrate was mixed with silica gel. Using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain the yellow intermediate (S-2). The obtained intermediate was then reacted with anhydrous acetonitrile, sodium hydride, and the second raw material at 70–90 °C. The reaction progress was monitored by TLC. After the reaction was complete, the mixture was neutralized with hydrochloric acid and methanol solution, and then mixed with silica gel. Again using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain the yellow final product.

[0108] According to a specific embodiment of this application, this application provides the use of the aforementioned 9,13-substituted berberine derivatives or physiologically acceptable salts or pharmaceutical compositions in the preparation, prevention and / or treatment of chronic atrophic gastritis.

[0109] According to a specific embodiment of this application, this application provides the use of the aforementioned 9,13-substituted berberine derivatives or physiologically acceptable salts or pharmaceutical compositions in the preparation, prevention and / or treatment of medicaments for chronic atrophic gastritis.

[0110] The present disclosure will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be construed as limiting the scope of the disclosure. Where specific techniques or conditions are not specified in the embodiments, they are performed in accordance with the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.

[0111] Example 1 Synthesis of 13-allyl-9-(allyloxy)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-1)

[0112] S-1, anhydrous acetonitrile, potassium carbonate, and 3-bromopropene (first raw material) were reacted at 60–70 °C. The reaction progress was monitored by TLC. After the reaction was complete, the mixture was cooled until the solid completely precipitated, filtered, and the filtrate was mixed with silica gel. Using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain a yellow intermediate. The obtained intermediate was then reacted with anhydrous acetonitrile, sodium hydride, and 3-bromopropene (second raw material) at 70–90 °C. The reaction progress was monitored by TLC. After the reaction was complete, the mixture was neutralized with hydrochloric acid and methanol solution, and then mixed with silica gel. Again using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain the yellow final product BBR-1. The NMR results of the final product are as follows:

[0113] 1 HNMR (500MHz, DMSO-d6) δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.13(d,J=8.8Hz,1H),6.99(t,J= 1.0Hz,1H),6.06(tt,J=11.2,5.6Hz,1H),6.04(s,2H),5.89(tt,J=16.4,8.1Hz,1H),5.40–5.32(m,2H),5.1 7(ddt,J=16.4,2.1,1.0Hz,1H),5.07(ddt,J=16.4,2.1,1.0Hz,1H),4.69(dt,J=5.6,1.0Hz,2H),4.64(ddd, J=7.3,4.6,1.7Hz,2H),3.90(s,3H),3.40(dt,J=8.1,1.0Hz,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H).

[0114] 13C NMR (125MHz, DMSO-d6) δ149.57,148.81,147.54,147.35,141.53,137.27,136.35,132.43,130.25,130.17,128.4 5,122.35,122.02,121.02,118.45,117.90,116.29,108.80,108.41,101.51,71.77,58.15,56.16,34.24,27.89.

[0115] ESI + :402.47.

[0116] Example 2 Synthesis of 13-allyl-9-(hex-5-en-1-yloxy)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-2)

[0117] The experimental procedure was the same as in Example 1, except that the first raw material was m-6-bromohexene and the second raw material was 3-bromopropene; the NMR results of the final product are as follows:

[0118] 1 HNMR (500MHz, DMSO-d6) δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1. 0Hz,1H),6.04(s,2H),5.96–5.73(m,2H),5.21–5.03(m,3H),4.97(ddt,J=17.1,2.1,1.0Hz,1H),4.64(ddd ,J=7.3,4.6,1.7Hz,2H),4.06(t,J=5.5Hz,2H),3.89(s,3H),3.40(dt,J=8.1,1.0Hz,2H),3.16(dddd,J=19 .3,7.6,4.6,1.0Hz,2H),2.06(tdt,J=7.9,6.9,1.1Hz,2H),1.77(tt,J=8.1,5.5Hz,2H),1.58–1.48(m,2H).

[0119] 13C NMR (125MHz, DMSO-d6) δ149.57,148.89,148.44,147.54,141.72,138.27,137.27,136.35,130.25,130.17,128.45,122.35, 122.04,121.24,118.39,116.29,114.91,108.80,108.41,101.51,71.86,58.15,56.16,34.24,33.27,28.87,27.89,25.76.

[0120] ESI + :444.22.

[0121] Example 3 Synthesis of 13-((E)-but-2-en-1-yl)-9-((E)-but-2-en-1-yl)oxy)-10-methoxy-5,6-dihydro-[1,3]dioxane[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-3)

[0122] The experimental procedure was the same as in Example 1, except that the first raw material was crotonyl bromide and the second raw material was crotonyl bromide; the NMR results of the final product are as follows:

[0123] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.13(d,J=8.8Hz,1H) ,6.99(t,J=1.1Hz,1H),6.04(s,2H),5.88–5.78(m,1H),5.74–5.56(m,3H),4.69(dt,J=4.3,1.0 Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),3.90(s,3H),3.43(dp,J=7.0,1.1Hz,2H),3.16(ddd d,J=19.3,7.6,4.6,1.0Hz,2H),1.67(ddt,J=5.4,1.8,1.0Hz,3H),1.62(dq,J=5.3,1.1Hz,3H).

[0124] 13C NMR (125MHz, DMSO-d6) δ149.57,148.81,147.54,141.52,136.71,130.37,130.25,129.74,128.40,128.26,127.61, 126.35,122.33,122.02,121.05,118.45,108.80,108.41,101.51,71.64,58.15,56.16,33.10,27.89,17.90,17.70.

[0125] ESI + :430.52.

[0126] Example 4 Synthesis of (E)-13-(but-2-en-1-yl)-10-methoxy-9-((3-methylbut-2-en-2-yl)oxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-4)

[0127] The experimental procedure was the same as in Example 1, except that the first raw material was 3,3-dimethylallyl bromide and the second raw material was crotonyl bromide; the NMR results of the final product are as follows:

[0128] 1 HNMR (500MHz, DMSO-d6) δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.13(d,J=8. 8Hz,1H),6.99(t,J=1.0Hz,1H),6.04(s,2H),5.88–5.78(m,1H),5.72–5.62(m,1H),5.3 0(dtq,J=4.8,3.2,1.7Hz,1H),4.67–4.61(m,4H),3.90(s,3H),3.43(dp,J=7.0,1.1Hz, 2H), 3.16 (dddd, J=19.3, 7.6, 4.6, 1.0Hz, 2H), 1.75 (q, J=1.1Hz, 6H), 1.64–1.59 (m, 3H).

[0129] 13C NMR (125MHz, DMSO-d6) δ149.57,148.81,147.72,147.54,141.52,136.71,136.42,130.37,130.25,128.40,128.26,127.61, 122.33,122.02,121.05,119.36,118.45,108.80,108.41,101.51,68.79,58.15,56.16,33.10,27.89,24.62,19.90,17.90.

[0130] ESI + :444.55.

[0131] Example 5 Synthesis of (E)-9-(but-2-en-1-yloxy)-10-methoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-5)

[0132] The experimental procedure was the same as in Example 1, except that the first raw material was crotonyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0133] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.13(d,J=8.8H z,1H),6.99(t,J=1.1Hz,1H),6.04(s,2H),5.74–5.56(m,2H),5.31(dddd,J=9.1,7.3,3.3 ,1.6Hz,1H),4.69(dt,J=4.2,1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),3.90(s,3H), 3.46(dp,J=7.5,1.1Hz,2H), 3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H), 1.70–1.64(m,9H).

[0134] 13C NMR (125MHz, DMSO-d6) δ149.57,148.81,147.54,141.50,136.77,130.34,130.25,129.75,129.74,128.30,126.35,123 .77,122.33,122.02,121.02,118.45,108.80,108.41,101.51,71.64,58.15,56.16,28.68,27.89,24.49,19.28,17.70.

[0135] ESI + :444.55.

[0136] Example 6 Synthesis of 10-methoxy-13-(3-methylbut-2-en-1-yl)-9-((3-methylbut-2-en-1-yloxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-6)

[0137] The experimental procedure was the same as in Example 1, except that the first raw material was 3,3-dimethylallyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0138] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,0H),7.32(d,J=8.8Hz,0H),6.04(s,1H),5.30(dtp,J=8.3,5.1,1.6Hz,1H),4.64(ddt,J=6.9,3.1,1.7H z,2H),3.90(s,1H),3.46(dp,J=7.4,1.1Hz,1H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,1H),1.75(q,J=1.1Hz,3H),1.68(q,J=1.2Hz,3H).

[0139] 13C NMR (125MHz, DMSO-d6) δ149.57,148.81,147.72,147.54,141.50,136.77,136.42,130.34,130.25,129.75,128.30,123.77,122 .33,122.02,121.02,119.36,118.45,108.80,108.41,101.51,68.79,58.15,56.16,28.68,27.89,24.62,24.50,19.90,19.28.

[0140] ESI + :458.58.

[0141] Example 7 Synthesis of 10-methoxy-13-(4-methylbenzyl)-9-((4-nitrobenzyl)oxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-7)

[0142] The experimental procedure was the same as in Example 1, except that the first raw material was p-nitrobenzyl bromide and the second raw material was p-methylbenzyl bromide; the NMR results of the final product are as follows:

[0143] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,0H),8.14–8.08(m,1H),7.61(dt,J=8.2, 1.0Hz,1H),7.37(d,J=8.8Hz,0H),7.18–7.06(m,2H),6.04(s,1H),5.16(t, J=1.0Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,1H),4.19(t,J=1.0Hz,1H),3. 90(s,1H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,1H),2.33(d,J=1.1Hz,1H).

[0144] 13C NMR (125MHz, DMSO-d6) δ149.57,148.97,148.25,147.54,147.13,141.49,140.63,138.17,137.14,136.95,131.12,130.81,129.27,1 28.72,128.45,128.18,123.76,123.65,122.54,120.58,118.47,108.80,108.18,101.51,73.04,57.39,56.16,36.00,27.89,21.04.

[0145] ESI + :561.2.

[0146] Example 8 Synthesis of 13-(3,5-dimethylbenzyl)-10-methoxy-9-((3-methylbut-2-en-1-yl)oxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-8)

[0147] The experimental procedure was the same as in Example 1, except that the first raw material was 3,3-dimethylallyl bromide and the second raw material was 3,5-dimethylbenzyl bromide; the NMR results of the final product are as follows:

[0148] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.49(s,1H),7.30(d,J=8.5Hz,1H),7.13(d,J=8. 8Hz,1H),6.99(t,J=1.0Hz,1H),6.89(dt,J=2.3,1.1Hz,2H),6.75(t,J=2.3Hz,1H),6.04 (s,2H),5.30(ddp,J=6.5,3.2,1.6Hz,1H),4.67–4.61(m,4H),4.45(t,J=1.0Hz,2H),3. 90(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.26(s,6H),1.75(q,J=1.1Hz,6H).

[0149] 13C NMR (125MHz, DMSO-d6) δ149.57,148.84,147.87,147.54,141.46,138.42,137.48,137.05,136.42,131.12,130.84,129.90,128.45, 128.11,123.78,122.54,120.25,119.36,118.41,108.80,108.18,101.51,68.79,57.39,56.16,36.40,27.89,24.62,21.09,19.90.

[0150] ESI + :508.64.

[0151] Example 9 Synthesis of 13-(3,5-dimethoxybenzyl)-9-(hex-5-yn-1-yloxy)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-9)

[0152] The experimental procedure was the same as in Example 1, except that the first raw material was 6-bromohexyne and the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0153] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,0H),7.49(s,0H),7.37(d,J=8.8Hz,0H),7.15(d,J=8.8Hz,0H),6.99(t,J=1.0H z,0H),6.46(dt,J=2.2,1.0Hz,1H),6.36(t,J=2.4Hz,1H),6.04(s,1H),4.64(ddd,J=7.3,4.6,1.7Hz,1H),4.11(t ,J=5.0Hz,1H),4.08(dt,J=9.5,1.0Hz,1H),4.00(dt,J=9.3,1.0Hz,1H),3.89(s,1H),3.79(s,3H),3.16(dddd,J= 19.3,7.6,4.6,1.0Hz,1H),2.47(td,J=5.9,3.0Hz,1H),1.80(tt,J=7.4,5.0Hz,1H),1.58(tt,J=7.5,5.6Hz,1H).

[0154] 13C NMR(125MHz,DMSO-d6)δ160.81,149.57,148.92,148.54,147.54,141.64,139.48,137.03,131.14,130.64,128.45,123.79,122.55,1 20.36,118.35,108.80,108.24,108.18,101.51,98.82,83.76,71.89,69.15,57.39,56.16,55.33,36.36,28.59,27.89,25.28,18.09.

[0155] ESI + :552.65.

[0156] Example 10 Synthesis of 9-(hept-6-en-1-yloxy)-10-methoxy-13-(4-nitrobenzyl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-10)

[0157] The experimental procedure was the same as in Example 1, except that the first raw material was 7-bromoheptene and the second raw material was p-nitrobenzyl bromide; the NMR results of the final product are as follows:

[0158] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.21–8.15(m,2H),7.55–7.47(m,3H),7.37(d,J=8.8Hz,1H),7.15(d,J=8.8Hz,1H),6.99 (t,J=1.0Hz,1H),6.04(s,2H),5.77(tt,J=10.3,6.8Hz,1H),5.10(ddt,J=10.3,2.0,1.0Hz,1H),4.98(ddt,J=10.2,2.1,1.0Hz ,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.20(t,J=1.1Hz,2H),4.07(t,J=6.0Hz,2H),3.89(s,2H),3.16(dddd,J=19.3,7.6,4 .6,1.0Hz,2H),2.03(tdt,J=8.0,6.9,1.1Hz,2H),1.70(qd,J=6.8,5.9Hz,2H),1.43(qd,J=6.6,5.6Hz,2H),1.39–1.30(m,2H).

[0159] 13C NMR (125MHz, DMSO-d6) δ149.57,149.54,148.92,148.54,147.54,143.96,141.64,138.86,137.13,131.12,130.87,128.79,128.45,123 .81,123.79,122.54,120.36,118.35,114.60,108.80,108.18,101.51,72.63,57.39,56.16,36.04,33.67,29.05,28.63,27.89,25.86.

[0160] ESI + :553.63.

[0161] Example 11 Synthesis of 9-(3-aminopropoxy)-13-(3-aminopropyl)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-11)

[0162] The experimental procedure was the same as in Example 1, except that the first raw material was 3-bromopropylamine and the second raw material was 3-bromopropylamine; the NMR results of the final product are as follows:

[0163] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.8Hz ,1H),6.99(t,J=1.0Hz,1H),6.04(s,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.08(t,J=5.6H z,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.93(pd,J=5.8,0.7Hz,2H),2 .87–2.77(m,6H),2.03(p,J=5.6Hz,2H),1.87(tt,J=8.1,5.3Hz,2H),1.74(t,J=6.3Hz,2H).

[0164] 13C NMR(125MHz,DMSO-d6)δ149.57,148.86,148.31,147.55,141.65,137.11,134.45,132.34,131.24,121.92,121 .89,120.78,118.39,109.19,108.80,101.51,70.41,58.81,56.16,40.83,37.04,29.70,29.09,28.76,27.89.

[0165] ESI + :436.53.

[0166] Example 12 Synthesis of 10-methoxy-9-(pent-4-en-1-yloxy)-13-pentyl-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-12)

[0167] The experimental procedure was the same as in Example 1, except that the first raw material was 5-bromopentene and the second raw material was 5-bromo-n-pentane; the NMR results of the final product are as follows:

[0168] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.8Hz,1H),7.01–6.97(m,1H),6.04(s,2H),5.7 4(tt,J=10.3,6.8Hz,1H),5.10(ddt,J=10.3,2.1,1.0Hz,1H),4.97(ddt,J=10.2,2.1,1.0Hz,1H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4 .04(t,J=6.8Hz,2H),3.89(s,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.86–2.76(m,1H),2.76–2.67(m,1H),2.14(tdt,J=8.0, 6.8,1.2Hz,2H),1.78(tt,J=8.4,6.8Hz,2H),1.68(tt,J=8.2,7.3Hz,2H),1.35(dddd,J=8.8,7.4,6.2,3.5Hz,4H),0.92–0.86(m,3H).

[0169] 13C NMR (125MHz, DMSO-d6) δ149.57,148.86,148.34,147.55,141.65,137.60,137.36,134.67,134.45,131.22,121.89,120.7 8,118.39,115.13,109.19,108.80,101.51,71.51,58.81,56.16,32.42,30.44,30.17,28.68,28.24,27.89,23.18,14.04.

[0170] ESI + :460.59.

[0171] Example 13 Synthesis of 9-(cyanomethoxy)-13-(hept-6-en-1-yl)-10-methoxy-5,6-dihydro-[1,3]dioxane[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-13)

[0172] The experimental procedure was the same as in Example 1, except that the first raw material was bromoacetylene and the second raw material was 7-bromoheptene; the NMR results of the final product are as follows:

[0173] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.14(d,J=8.8Hz,1H),6.99(t,J =1.0Hz,1H),6.04(s,2H),5.77(tt,J=17.1,6.8Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),5.01–4.94(m, 1H),4.95(s,3H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H) ,2.78(t,J=8.5Hz,2H),2.03(tdt,J=7.8,6.7,1.1Hz,2H),1.69(tt,J=8.5,6.8Hz,2H),1.39–1.30(m,4H).

[0174] 13C NMR (125MHz, DMSO-d6) δ149.57,148.68,147.55,146.68,141.53,139.08,137.37,134.69,134.45,131.06,121.89,121.84 ,120.85,118.58,115.38,114.41,109.19,108.80,101.51,58.81,57.53,56.16,33.79,30.56,28.72,28.49,28.44,27.89.

[0175] ESI + :457.55.

[0176] Example 14 Synthesis of 9-(allyloxy)-13-(hex-5-en-1-yl)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-14)

[0177] The experimental procedure was the same as in Example 1, except that the first raw material was 3-bromopropene and the second raw material was 6-bromohexene; the NMR results of the final product are as follows:

[0178] 1 HNMR (500MHz, DMSO-d6) δ9.94(s,1H),7.47(s,1H),7.25(d,J=8.8Hz,1H),7.13(d,J=8.8Hz,1H),6.99(t,J=1.1Hz,1H),6.06(tt,J=11 .2,5.6Hz,1H),6.04(s,2H),5.77(tt,J=10.1,6.9Hz,1H),5.40–5.32(m,2H),5.10(ddt,J=10.3,2.0,1.0Hz,1H),4.98(ddt,J=10.2,2. 1,1.0Hz,1H),4.69(dt,J=5.6,1.0Hz,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),3.90(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2 .83(dt,J=16.1,8.0Hz,1H),2.75(dt,J=15.9,8.0Hz,1H),2.09–2.01(m,2H),1.66(tt,J=8.1,6.0Hz,2H),1.41(tt,J=7.8,6.1Hz,2H).

[0179] 13C NMR(125MHz,DMSO-d6)δ149.57,148.78,147.55,147.09,141.47,138.29,137.37,134.69,134.45,132.43,131.24,121.89, 121.87,120.90,118.47,117.90,114.90,109.19,108.80,101.51,71.77,58.81,56.16,33.39,30.38,28.12,27.98,27.89.

[0180] ESI + :444.55.

[0181] Example 15 Synthesis of 10-methoxy-13-(pent-4-en-1-yl)-9-(pentoxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-15)

[0182] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopentane and the second raw material was 5-bromopentene; the NMR results of the final product are as follows:

[0183] 1 HNMR (500MHz, DMSO-d6) δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1.0Hz,1H),6.04( s,2H),5.71(tt,J=17.2,6.8Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=17.1,2.1,1.0Hz,1H),4.63(ddd,J=7.6 ,4.9,1.2Hz,2H),4.07(t,J=5.7Hz,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.87(t,J=9.2Hz,2H),2.14(t dt,J=8.0,6.9,1.1Hz,2H),1.76(tt,J=7.4,5.7Hz,2H),1.65(tt,J=9.3,7.9Hz,2H),1.46–1.31(m,4H),0.90(t,J=6.8Hz,3H).

[0184] 13C NMR (125MHz, DMSO-d6) δ149.57,148.86,148.32,147.55,141.65,138.25,137.10,134.45,133.08,131.24,121.91,121.89,12 0.78,118.39,114.91,109.19,108.80,101.51,71.86,58.81,56.16,33.02,30.13,28.87,28.46,27.89,27.85,22.46,13.97.

[0185] ESI + :460.59.

[0186] Example 16 Synthesis of O-methoxy-9-((4-methylbenzyl)oxy)-13-(oct-7-yl-1-yl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-16)

[0187] The experimental procedure was the same as in Example 1, except that the first raw material was p-methylbenzyl bromide and the second raw material was 8-bromoheptyne; the NMR results of the final product are as follows:

[0188] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.35–7.27(m,3H),7.15(dd,J=8.3,2.7Hz,3H),6.99(t ,J=1.1Hz,1H),6.04(s,2H),5.16(t,J=1.0Hz,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),3.90(s,2H),3.16(d ddd,J=19.3,7.6,4.6,1.0Hz,2H),2.78(t,J=8.5Hz,2H),2.34(d,J=1.0Hz,2H),2.12(td,J=5.9,3.0Hz,2H ),2.06(t,J=2.9Hz,1H),1.68(tt,J=8.4,7.2Hz,2H),1.47(dq,J=6.8,5.8,5.3Hz,2H),1.44–1.34(m,4H).

[0189] 13C NMR(125MHz,DMSO-d6)δ149.57,148.91,147.55,146.87,141.47,138.34,137.37,134.68,134.45,133.72,131.24,129.09,128.12,121.89,1 21.84,120.81,118.58,109.19,108.80,101.51,83.81,73.04,69.15, 58.81,56.16,30.56,28.81,28.59,28.38,28.04,27.89,21.05,17.91.

[0190] ESI + :534.68.

[0191] Example 17 Synthesis of 13-(hept-6-yn-1-yl)-9-(hept-6-yn-1-yloxy)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-17)

[0192] The experimental procedure was the same as in Example 1, except that the first raw material was 7-bromoheptyne and the second raw material was 7-bromoheptyne; the NMR results of the final product are as follows:

[0193] 1 H NMR (500MHz, DMSO-d6) δ9.94 (s, 0H), 7.32 (d, J = 8.5Hz, 0H), 6.04 (s, 1H), 4.63 ( ddd,J=7.6,4.9,1.2Hz,1H),4.06(t,J=6.1Hz,1H),3.89(s,1H),3.16(dddd,J= 19.3,7.6,4.6,1.0Hz,1H),2.78(t,J=8.5Hz,1H),2.11(td,J=5.9,3.0Hz,2H), 2.06(t,J=2.9Hz,1H),1.81–1.71(m,2H),1.59–1.46(m,3H),1.43–1.35(m,1H).

[0194] 13C NMR (125MHz, DMSO-d6) δ149.57,148.86,148.32,147.55,141.65,137.36,134.68,134.45,131.22,121.89,120.76,118.39,109.19 ,108.80,101.51,83.82,83.79,72.63,69.16,69.15,58.81,56.16,30.59,29.03,28.64,28.07,28.01,27.89,27.85,25.70,17.92.

[0195] ESI + :510.65.

[0196] Example 18 Synthesis of 9-(hept-6-en-1-yloxy)-13-(hex-5-yn-1-yl)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-18)

[0197] The experimental procedure was the same as in Example 1, except that the first raw material was 6-bromohexene and the second raw material was 6-bromohexyne; the NMR results of the final product are as follows:

[0198] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1.0Hz,1H),6.0 4(s,2H),5.80(tt,J=17.1,6.8Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=17.1,2.1,1.0Hz,1H),4.63(ddd,J =7.6,4.9,1.2Hz,2H),4.06(t,J=5.5Hz,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.83(dt,J=15.8,7.3H z,1H),2.74(dt,J=15.6,7.3Hz,1H),2.46(td,J=5.7,3.0Hz,2H),2.11–2.02(m,3H),1.84–1.72(m,4H),1.63–1.48(m,4H).

[0199] 13C NMR (125MHz, DMSO-d6) δ149.57,148.86,148.32,147.55,141.65,138.27,137.36,134.67,134.45,131.22,121.89,120.74,118. 39,114.91,109.19,108.80,101.51,83.79,71.86,69.15,58.81,56.16,33.27,30.57,28.87,27.89,27.61,27.50,25.76,18.24.

[0200] ESI + :484.62.

[0201] Example 19 Synthesis of 9-(3-aminopropoxy)-13-(but-3-yn-1-yl)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-19)

[0202] The experimental procedure was the same as in Example 1, except that the first raw material was 3-bromopropylamine and the second raw material was 4-bromobutyne; the NMR results of the final product are as follows:

[0203] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d ,J=8.8Hz,1H),6.99(t,J=1.1Hz,1H),6.04(s,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2 H),4.08(t,J=5.6Hz,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2 .97–2.85(m,4H),2.85–2.78(m,4H),2.47(t,J=3.0Hz,1H),2.03(p,J=5.6Hz,2H).

[0204] 13C NMR(125MHz,DMSO-d6)δ149.57,148.86,148.31,147.55,141.59,136.37,134.50,131.26,130.54,122.13,121.90 ,120.86,118.39,109.19,108.80,101.51,83.35,70.41,69.74,58.81,56.16,37.04,30.41,28.76,27.89,18.02.

[0205] ESI + :431.51.

[0206] Example 20 Synthesis of 13-(hexane-5-yn-1-yl)-10-methoxy-9-(propane-2-yn-1-yloxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-20)

[0207] The experimental procedure was the same as in Example 1, except that the first raw material was 3-bromopropyne and the second raw material was 6-bromohexyne; the NMR results of the final product are as follows:

[0208] 1 HNMR (500MHz, DMSO-d6) δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.14(d,J=8.8Hz,1H),6.99(t,J=1. 0Hz,1H),6.04(s,2H),4.85(d,J=2.9Hz,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),3.89(s,2H),3.35(s,0H),3.35 (d,J=6.1Hz,0H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.83(dt,J=15.8,7.3Hz,1H),2.74(dt,J=15.6,7.3 Hz,1H),2.46(td,J=5.7,3.0Hz,2H),2.06(t,J=3.1Hz,1H),1.79(tt,J=7.4,6.1Hz,2H),1.59(p,J=5.9Hz,2H).

[0209] 13C NMR (125MHz, DMSO-d6) δ149.57,148.63,147.64,147.55,141.59,137.37,134.68,134.45,131.16,121.89,121.84,120.7 7,118.58,109.19,108.80,101.51,83.79,78.88,76.69,69.15,61.36,58.81,56.16,30.57,27.89,27.61,27.50,18.24.

[0210] ESI + :440.52.

[0211] Example 21 Synthesis of (E)-9-(but-2-en-1-yloxy)-13-(cyanomethyl)-10-methoxy-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-21)

[0212] The experimental procedure was the same as in Example 1, except that the first raw material was crotonyl bromide and the second raw material was bromoacetonitrile; the NMR results of the final product are as follows:

[0213] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.31(d,J=8.8Hz,1H),7.13(d,J =8.8Hz,1H),6.99(t,J=1.0Hz,1H),6.04(s,2H),5.73–5.64(m,1H),5.64–5.56(m,1H ),4.69(dt,J=4.4,1.1Hz,2H),4.63(ddd,J=7.3,4.6,1.1Hz,2H),4.20(s,2H),3.90 (s,2H),3.16(dddd,J=17.3,7.3,4.6,1.0Hz,2H),1.67(ddt,J=5.4,1.7,1.0Hz,3H).

[0214] 13C NMR (125MHz, DMSO-d6) δ149.57,148.84,147.79,147.51,141.44,136.11,130.26,129.74,128.89,127.92,126. 35,122.75,121.96,121.08,118.41,117.11,108.80,108.36,101.51,71.64,58.16,56.16,27.89,18.88,17.70.

[0215] ESI + :415.47.

[0216] Example 22 Synthesis of 10-methoxy-13-(4-methylbenzyl)-9-((4-methylbenzyl)oxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-22)

[0217] The experimental procedure was as follows: Berberine and the first raw material, tetramethylbenzyl bromide, were dissolved in acetonitrile and reacted in an acidic environment (NaH). The mixture was then packed into a silica gel column and eluted with chloroform and methanol to obtain a demethylated product. The demethylated product was then reacted with the second raw material, tetramethylbenzyl bromide, and eluted with a column to obtain the final product. The NMR results are as follows:

[0218] 1 H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 7.49 (s, 1H), 7.37 (d, J = 8.8Hz, 1H), 7.30 (dt, J=7.9,1.1Hz,2H),7.18–7.11(m,5H),7.11–7.06(m,2H),6.99(t,J=1.0Hz,1H),6.0 4(s,2H),5.16(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz ,2H),3.90(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.34(d,J=1.8Hz,6H).

[0219] 13C NMR (125MHz, DMSO-d6) δ149.57,148.97,147.54,147.13,141.49,138.34,138.17,137.14,136.95,133.72,131.12,130.81,129.27,129.09,128 .45,128.15(d,J=8.1Hz),123.76,122.54,120.58,118.47,108.80,108 .18,101.51,73.04,57.39,56.16,36.00,27.89,21.05(d,J=1.0Hz).ESI + :530.23.

[0220] Example 23 Synthesis of 10-methoxy-13-(4-methylbenzyl)-9-((3-methylbenzyl)oxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-23)

[0221] The experimental procedure differs from that in Example 22 only in that the second raw material is 3-methylbenzyl bromide; the NMR results of the final product are as follows:

[0222] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.40–7.30(m,2H),7.25–7.18(m,2H),7.18–7.06(m,6H),6.04(s,2H),5.14(t,J=1.1Hz,2H), 4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz,2H),3.90(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.35–2.31(m,6H).

[0223] 13C NMR(125MHz,DMSO-d6)δ149.57,148.97,147.54,147.13,141.49,138.17,13 7.42,137.14,136.95,135.58,131.12,130.81,129.27,128.91(d,J=9.1Hz) ,128.48(d,J=7.2Hz),128.18,126.04,123.76,122.54,120.58,118.47,108 .80,108.18,101.51,73.92,57.39,56.16,36.00,27.89,21.05(d,J=1.0Hz).

[0224] ESI + :530.23.

[0225] Example 24 Synthesis of 9-((3,5-dimethoxybenzyl)oxy)-10-methoxy-13-(4-methylbenzyl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-24)

[0226] The experimental procedure was the same as in Example 22, except that the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0227] 1 HNMR(500MHz,DMSO-d6)δ7.37(d,J=8.8Hz,1H),7.18–7.06(m,5H),6.63(dt ,J=2.3,1.2Hz,2H),6.39(t,J=2.4Hz,1H),6.04(s,2H),5.14(t,J=1.0Hz,2 H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz,2H),3.90(s,3H),3 .79(s,6H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.33(d,J=1.1Hz,3H).

[0228] 13C NMR (125MHz, DMSO-d6) δ160.51,149.57,148.97,147.54,147.26,141.49,138.17,137.84,137.14,136.95,131.12,130.81,129.27,128 .45,128.18,123.76,122.54,120.36,118.47,108.80,108.18,107.19,101.51,99.53,73.58,57.39,56.16,55.33,36.00,27.89,21.04.

[0229] ESI + :576.24.

[0230] Example 25 Synthesis of 9-(3,5-di-tert-butylbenzyl)oxy)-10-methoxy-13-(4-methylbenzyl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-25)

[0231] The experimental procedure was the same as in Example 22, except that the second raw material was 2-butenyl bromide; the NMR results of the final product are as follows:

[0232] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.30(d,J=8.5Hz,1H),7.17–7.06(m,5H ),6.04(s,2H),5.74–5.56(m,2H),4.69(dt,J=4.3,1.0Hz,2H),4.64(ddd,J=7 .3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz,2H),3.90(s,3H),3.16(dddd,J=19.3,7 .6,4.6,1.0Hz,2H),2.33(d,J=1.1Hz,3H),1.67(ddt,J=5.4,1.7,1.0Hz,3H).

[0233] 13C NMR(125MHz,DMSO-d6)δ149.57,148.84,147.60(d,J=15.7Hz),141.46,138.17,137.14,136.95,131.12,130.81,129.74,129.27,1 28.45,128.18,126.35,123.78,122.54,120.25,118.41,108.80,108.18,101.51,71.64,57.39,56.16,36.00,27.89,21.04,17.70.

[0234] ESI + :480.22.

[0235] Example 26 Synthesis of 9-(hept-6-yn-1-yloxy)-10-methoxy-13-(4-methylbenzyl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-26)

[0236] The experimental procedure was the same as in Example 22, except that the second raw material was 7-bromohept-1-yne; the NMR results of the final product are as follows:

[0237] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.15(d,J=6.8Hz,1H),7.15–7 .06(m,4H),6.04(s,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz,2H),4.06(t,J =6.1Hz,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.33(d,J=1.1Hz,3H),2 .11(td,J=5.8,2.9Hz,2H),2.06(t,J=2.9Hz,1H),1.75(p,J=6.3Hz,2H),1.57–1.46(m,4H).

[0238] 13C NMR (125MHz, DMSO-d6) δ149.57,148.92,148.54,147.54,141.64,138.17,137.13,136.95,131.12,130.81,129.27,128.45,128.18,123.79, 122.54,120.36,118.35,108.80,108.18,101.51,83.79,72.63,69.15 ,57.39,56.16,36.00,29.03,27.87(d,J=4.1Hz),25.70,21.04,17.92.

[0239] ESI + :520.25.

[0240] Example 27 Synthesis of 9-(hept-6-en-1-yloxy)-10-methoxy-13-(4-methylbenzyl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-27)

[0241] The experimental procedure was the same as in Example 22, except that the second raw material was 7-bromo-1-heptene; the NMR results of the final product are as follows:

[0242] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.49(s,1H),7.37(d,J=8.8Hz,1H),7.15(d,J=6.8Hz,1H),7.15–7.06(m,4H),6.99(t,J=1.1 Hz,1H),6.04(s,2H),5.77(tt,J=17.1,6.8Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=17.1,2.1,1.1Hz,1H),4.64(d dd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz,2H),4.07(t,J=6.0Hz,2H),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2. 33(d,J=1.1Hz,3H),2.03(tdt,J=8.0,6.9,1.1Hz,2H),1.70(qd,J=6.9,5.9Hz,2H),1.43(qd,J=6.6,5.6Hz,2H),1.40–1.30(m,2H).

[0243] 13C NMR (125MHz, DMSO-d6) δ149.57,148.92,148.54,147.54,141.64,138.86,138.17,137.13,136.95,131.12,130.81,129.27,128.45,128.18 ,123.79,122.54,120.36,118.35,114.60,108.80,108.18,101.51,7 2.63,57.39,56.16,36.00,33.67,29.05,28.63,27.89,25.86,21.04.

[0244] ESI + :522.26.

[0245] Example 28 Synthesis of 9-((5-cyanopentyl)oxy)-10-methoxy-13-(4-methylbenzyl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-28)

[0246] The experimental procedure was the same as in Example 22, except that the second raw material was 6-bromohexanonitrile; the NMR results of the final product are as follows:

[0247] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.18–7.06(m,5H),6.04 (s,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0Hz,2H),4.06(t,J=6.1Hz,2H ),3.89(s,3H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.39(t,J=5.9Hz,2H),2.33 (d,J=1.1Hz,3H),1.75(p,J=6.2Hz,2H),1.67(p,J=5.9Hz,2H),1.49(p,J=6.3Hz,2H).

[0248] 13C NMR (125MHz, DMSO-d6) δ149.57,148.92,148.54,147.54,141.64,138.17,137.13,136.95,131.12,130.81,129.27,128.45,128.18,12 3.79,122.54,120.36,119.41,118.35,108.80,108.18,101.51,72.63,57.39,56.16,36.00,29.02,27.89,25.52,24.65,21.04,17.06.

[0249] ESI + :521.24.

[0250] Example 29 Synthesis of 10-methoxy-13-(4-methylbenzyl)-9-((3-methylbut-2-en-1-yl)oxy)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinolino[3,2-a]isoquinolino-7-onium (BBR-29)

[0251] The experimental procedure was the same as in Example 22, except that the second raw material was 1-bromo-3-methyl-2-butene; the NMR results of the final product are as follows:

[0252] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.49(s,1H),7.30(d,J=8.5Hz,1H),7.17–7 .10(m,3H),7.10–7.06(m,2H),6.99(t,J=1.0Hz,1H),6.04(s,2H),5.30(ddp,J=6 .5,3.2,1.7Hz,1H),4.67–4.61(m,4H),4.19(t,J=1.0Hz,2H),3.90(s,3H),3.16( dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.33(d,J=1.1Hz,3H),1.75(q,J=1.1Hz,6H).

[0253] 13C NMR(125MHz,DMSO-d6)δ149.57,148.84,147.87,147.54,141.46,138.17,137.14,136.95,136.42,131.12,130.81,129.27,128.45, 128.18,123.78,122.54,120.25,119.36,118.41,108.80,108.18,101.51,68.79,57.39,56.16,36.00,27.89,24.62,21.04,19.90.

[0254] ESI + :494.23.

[0255] Example 30 Synthesis of 10-methoxy-9-((4-methylbenzyl)oxy)-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxoquino[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-30)

[0256] The experimental procedure was the same as in Example 22, except that the first raw material was p-methylbenzyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0257] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.30(dt,J=7.9,1.1Hz, 2H),7.15(dd,J=8.4,2.6Hz,3H),6.99(t,J=1.0Hz,1H),6.04(s,2H),5.31(dddd,J=9.1,7.3,3. 3,1.6Hz,1H),5.16(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),3.90(s,3H),3.49–3.43 (m,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.34(d,J=1.1Hz,2H),1.68(q,J=1.2Hz,6H).

[0258] 13C NMR(125MHz,DMSO-d6)δ149.57,148.94,147.54,147.03,141.50,138.34,136.77,133.72,130.34,130.25,129.75,129.09,128.30, 128.12,123.77,122.33,121.98,121.14,118.52,108.80,108.41,101.51,73.04,58.15,56.16,28.68,27.89,24.49,21.05,19.28.

[0259] ESI+: 494.61.

[0260] Example 31 Synthesis of 10-methoxy-9-((3-methylbenzyl)oxy)-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxoquino[4,5-g]isoquinolinyl[3,2-a]isoquinolin-7-onium (BBR-31)

[0261] The experimental procedure was the same as in Example 22, except that the first raw material was 3-methylbenzyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0262] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.33(ddt,J=7.5,2.2,1.1 Hz,1H),7.25–7.18(m,2H),7.18–7.08(m,2H),6.99(t,J=1.0Hz,1H),6.04(s,2H),5.31(dddd,J= 9.1,7.3,3.3,1.6Hz,1H),5.14(t,J=1.1Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),3.90(s,3H), 3.49–3.43(m,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.33(s,2H),1.68(q,J=1.2Hz,6H).

[0263] 13C NMR(125MHz,DMSO-d6)δ149.57,148.94,147.54,147.03,141.50,137.42,136.77,135.58,130.34,130.25,129.75,128.95,128.88,128.51, 128.30,126.04,123.77,122.33,121.98,121.14,118.52,108.80,108 .41,101.51,73.92,58.15,56.16,28.68,27.89,24.49,21.05,19.28.

[0264] ESI + :494.61.

[0265] Example 32 Synthesis of 9-(hept-6-en-1-yloxy)-10-methoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxoquino[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-32)

[0266] The experimental procedure was the same as in Example 22, except that the first raw material was 7-bromoheptene and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0267] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1.0Hz,1H),6.04(s, 2H),5.77(tt,J=17.1,6.8Hz,1H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=1 7.1, 2.1, 1.1Hz, 1H), 4.64 (ddd, J=7.3, 4.6, 1.7Hz, 2H), 4.07 (t, J=6.0Hz, 2H), 3.46 (dp, J=7.4, 1.0Hz, 2H), 3.16 (dddd, J=19. 3,7.6,4.6,1.0Hz,2H),2.03(tdt,J=8.0,6.9,1.0Hz,2H),1.75–1.66(m,8H),1.43(qd,J=6.6,5.6Hz,2H),1.39–1.30(m,2H).

[0268] 13 C NMR (125MHz, DMSO-d6) δ149.57,148.88,148.44,147.54,141.69,138.86,136.76,130.25,130.16,129.75,128.30,123.77,122.33,12 2.04,121.33,118.39,114.60,108.80,108.41,101.51,72.63,58.15,56.16,33.67,29.05,28.68,28.63,27.89,25.86,24.49,19.28.

[0269] ESI + :486.63.

[0270] Example 33 Synthesis of 9-(hept-6-yn-1-yloxy)-10-methoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxo[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-33)

[0271] The experimental procedure was the same as in Example 22, except that the first raw material was 7-bromohept-1-yne and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0272] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.15(d,J=8.8Hz,1H),6.99(t,J =1.0Hz,1H),6.04(s,2H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),4.64(dddd,J=7.3,4.6,1.7Hz,2H),4. 06(t,J=6.1Hz,2H),3.46(dp,J=7.4,1.0Hz,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.11(td,J= 5.8,3.0Hz,2H),2.06(t,J=2.9Hz,1H),1.75(p,J=6.3Hz,2H),1.68(q,J=1.2Hz,6H),1.57–1.46(m,4H).

[0273] 13C NMR(125MHz,DMSO-d6)δ149.57,148.88,148.44,147.54,141.69,136.76,130.25,130.16,129.75,128.30,123.77,122.33,122.04,1 21.33,118.39,108.80,108.41,101.51,83.79,72.63,69.15,58.15,56.16,29.03,28.68,27.89,27.85,25.70,24.49,19.28,17.92.

[0274] ESI + :484.62.

[0275] Example 34 Synthesis of 9-(hex-5-en-1-yloxy)-10-methoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxoquino[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-34)

[0276] The experimental procedure was the same as in Example 22, except that the first raw material was 6-bromo-1-hexene and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0277] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1.0Hz,1H),6.04(s,2H), 5.79(tt,J=10.3,6.8Hz,1H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),5.10(ddt,J=10.3,2.0,1.0Hz,1H),4.98(ddt,J=10.2,2.1 ,1.0Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.06(t,J=5.5Hz,2H),3.89(s,3H),3.46(dq,J=7.3,1.0Hz,2H),3.16(dddd,J=19 .3,7.6,4.6,1.0Hz,2H),2.06(tdt,J=7.9,6.9,1.0Hz,2H),1.77(tt,J=8.1,5.5Hz,2H),1.68(q,J=1.1Hz,6H),1.58–1.48(m,2H).

[0278] 13 C NMR (125MHz, DMSO-d6) δ149.57,148.89,148.44,147.54,141.69,138.27,136.76,130.25,130.16,129.75,128.30,123.77,122.33 ,122.04,121.33,118.39,114.91,108.80,108.41,101.51,71.86,58.15,56.16,33.27,28.87,28.68,27.89,25.76,24.49,19.28.

[0279] ESI + :472.60.

[0280] Example 35 Synthesis of 9-(allyloxy)-10-methoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydro-[1,3]dioxoxy[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-35)

[0281] The experimental procedure was the same as in Example 22, except that the first raw material was 3-bromopropene and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0282] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.8Hz,1H),7.13(d,J=8.8Hz,1H ),6.99(t,J=1.0Hz,1H),6.06(tt,J=16.9,5.6Hz,1H),6.04(s,2H),5.39(ddt,J=16.9,2.1,1. 0Hz,1H),5.35–5.27(m,2H),4.69(dt,J=5.6,1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),3. 90(s,3H),3.49–3.44(m,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),1.68(q,J=1.2Hz,6H).

[0283] 13C NMR (125MHz, DMSO-d6) δ149.57,148.81,147.54,147.35,141.50,136.77,132.43,130.34,130.25,129.75,128.30,123. 77,122.33,122.02,121.02,118.45,117.90,108.80,108.41,101.51,71.77,58.15,56.16,28.68,27.89,24.49,19.28.

[0284] ESI + :430.52.

[0285] Example 36 Synthesis of 10-methoxy-13-(3-methylbut-2-en-1-yl)-9-(prop-2-yn-1-acyloxy)-5,6-dihydro-[1,3]dioxoquino[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-36)

[0286] The experimental procedure was the same as in Example 22, except that the first raw material was 3-bromopropyne and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0287] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.41–7.36(m,1H),7.14(d,J=8.5Hz, 1H),6.99(t,J=1.1Hz,1H),6.04(s,2H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),4.85(d, J=2.9Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),3.89(s,3H),3.46(dp,J=7.3,1.0Hz,2H ), 3.35 (d, J = 6.1Hz, 0H), 3.16 (dddd, J = 19.3, 7.6, 4.6, 1.0Hz, 2H), 1.68 (q, J = 1.2Hz, 6H).

[0288] 13C NMR (125MHz, DMSO-d6) δ149.57,148.67,147.76,147.54,141.62,136.77,130.25,130.24,129.75,128.30,123.77,122 .33,121.98,120.97,118.52,108.80,108.41,101.51,78.88,76.69,61.36,58.15,56.16,28.68,27.89,24.49,19.28.

[0289] ESI + :428.51.

[0290] Example 37 Synthesis of 13-heptyl-10-methoxy-9-(pent-4-en-1-yloxy)-5,6-dihydro-[1,3]dioxool[4,5-g]isoquinoline[3,2-a]isoquinoline-7-ammonium-onium (BBR-37)

[0291] The experimental procedure is the same as in Example 1 of this application, except that the first raw material is 5-bromopentene and the second raw material is bromoheptane; the NMR results of the final product are as follows:

[0292] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1.1Hz,1H),6.04(s ,2H),5.74(tt,J=10.3,6.8Hz,1H),5.10(ddt,J=10.3,2.1,1.0Hz,1H),4.97(ddt,J=10.2,2.1,1.0Hz,1H),4.64(dd,J=7.5,4.8 Hz,1H),4.07(dd,J=7.4,4.8Hz,1H),4.04(t,J=6.8Hz,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.77(t,J=8.5Hz,2H),2. 14(tdt,J=8.1,6.9,1.2Hz,2H),1.78(tt,J=8.4,6.8Hz,2H),1.69(tt,J=8.4,7.2Hz,2H),1.37–1.22(m,8H),0.94–0.85(m,3H).

[0293] 13C NMR (125MHz, DMSO-d6) δ149.57,148.86,148.34,147.55,141.65,137.60,137.36,134.67,134.45,131.22,121.89,120.78,118. 39,115.13,109.19,108.80,101.51,71.51,58.64,56.16,31.77,30.56,30.17,29.19,28.81,28.75,28.68,27.89,22.68,14.06.

[0294] ESI + :488.65.

[0295] Example 38 Synthesis of 13-decyl-10-methoxy-9-(pent-4-en-1-yloxy)-5,6-dihydro-[1,3]dioxool[4,5-g]isoquinoline[3,2-a]isoquinoline-7-onium (BBR-38)

[0296] The experimental procedure was the same as in Example 1, except that the first raw material was 5-bromopentene and the second raw material was 1-bromodecane; the NMR results of the final product are as follows:

[0297] 1 HNMR(500MHz,DMSO-d6)δ9.94(s,1H),7.47(s,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.8Hz,1H),6.99(t,J=1.0Hz,1H),6.04(s ,2H),5.74(tt,J=10.3,6.8Hz,1H),5.10(ddt,J=10.3,2.1,1.0Hz,1H),4.97(ddt,J=10.2,2.1,1.0Hz,1H),4.64(dd,J=7.5,4.8 Hz,1H),4.07(dd,J=7.4,4.8Hz,1H),4.04(t,J=6.8Hz,2H),3.16(dddd,J=19.3,7.6,4.6,1.0Hz,2H),2.78(t,J=8.5Hz,2H),2.1 4(tdt,J=8.1,6.9,1.2Hz,2H),1.78(tt,J=8.4,6.8Hz,2H),1.69(tt,J=8.4,7.2Hz,2H),1.39–1.23(m,14H),0.94–0.86(m,3H).

[0298] 13C NMR (125MHz, DMSO-d6) δ149.57,148.86,148.34,147.55,141.65,137.60,137.36,134.67,134.45,131.22,121.89,120.78,118.39,115 .13,109.19,108.80,101.51,71.51,58.64,56.16,31.74,30.56,30.17,29.54,29.33,29.21,29.11,28.81,28.68,27.89,22.67,14.06.

[0299] ESI + :530.73.

[0300] Example 39: Berberine derivatives improve chronic atrophic gastritis

[0301] In vitro experiments

[0302] Cells used: Human gastric mucosal epithelial cells GES-1;

[0303] Drugs used: ELISA kit, MNNG, and 21 small molecule compounds synthesized based on BBR (compounds synthesized in Examples 1-21);

[0304] Experimental protocol: ELISA was used to screen for drugs that are sensitive to N-methyl-N-nitro-nitrosoguanidine (MNNG)-induced human gastric mucosal epithelial GES-1 cells.

[0305] A precancerous inflammatory cell model was established by inducing GES-1 with MNNG.

[0306] GES-1 cells were set as the blank group, and cells that successfully formed the model were divided into control group and drug-containing group (grouped according to the 21 compounds screened by chemical synthesis in the previous stage (compounds synthesized in Examples 1-21), and labeled as berberine-1, berberine-2, berberine-3... and so on).

[0307] The IL-1β content in the supernatant was measured using ELISA. Twenty-one compounds (compounds synthesized in Examples 1-21) were added at the same concentration and cultured in DMEM medium containing 10% fetal bovine serum for 24 hours. The results were compared with the blank group and the control group. Statistical analysis was performed to determine the inhibitory rate of the drug on MNNG-induced inflammation in human gastric mucosal epithelial GES-1 cells.

[0308] To investigate the anti-inflammatory, especially anti-CAG, activities of 21 compounds synthesized based on berberine (compounds synthesized in Examples 1-21), this study induced GES-1 cells using MNNG. Wild-type GES-1 cells were designated as the control group, and MNNG-induced GES-1 cells were designated as the control, berberine, berberine-1, berberine-2, and so on up to berberine-21. The corresponding drug at the same concentration (20 μmol / L) was added to each cell, and after culturing under the same conditions for 24 h, the IL-1β content in the cell supernatant was measured using an ELISA kit, and statistical analysis was performed.

[0309] The results, shown in Figure 1, illustrate the effects of BBR and the berberine derivative of this application on the IL-1β content in the supernatant of MNNG-induced GES-1 cells. The results indicate that, compared to the control group BBR, the berberine derivative of this application exhibits better inhibition of inflammatory factors.

[0310] Furthermore, the toxicity of 21 compounds was determined using the CCK8 assay. GES-1 cells were treated with berberine and the berberine derivative of this application, and cell viability was detected. The results are shown in Figure 2, indicating that the berberine derivative of this application has low drug toxicity to cells, similar to berberine.

[0311] To verify the anti-inflammatory effect of berberine-5 in vitro, GES-1 cells were induced to produce inflammation with MNNG (70 nmol / mL), and then the induced cells were treated with berberine and the above 21 compounds (compounds synthesized in Examples 1-21). The experimental results are shown in Table 1.

[0312] Simultaneously, GES-1 cells were induced to produce inflammation with MNNG (70 nmol / mL), and then the induced cells were treated with berberine and the compounds synthesized in Examples 22-38 above (the corresponding groups are berberine-22, berberine-23... and so on up to berberine-38). The experimental results are shown in Table 2.

[0313] Compared with the control group, the levels of inflammatory factors IL-6 and TNF-α secreted by cells in each group decreased to varying degrees after drug administration.

[0314] Table 1

[0315] Table 2

[0316] (I) In vivo experiments

[0317] 1. Laboratory animals

[0318] 6-8 week old female C57BL / 6 mice

[0319] 2. Reagent preparation

[0320] (1) Physiological saline solution, purchased medical grade 0.9% NaCl aqueous solution;

[0321] (2) MNNG: Weigh 50 mg of MNNG and prepare a 50 mg / mL drug solution using 0.9% NaCl aqueous solution;

[0322] (3) Ranitidine, weigh 75mg and use 0.9% NaCl aqueous solution to prepare a drug solution of 75mg / mL;

[0323] (4) CMC: Weigh 500mg of CMC and add it to 50mL of pure water to prepare a 10mg / mL drug solution;

[0324] (5) Berberine: Weigh 3g and prepare a 3mg / mL drug solution using 10mg / mL CMC solution;

[0325] (6) Berberine-5, weigh 3g and use 10mg / mL CMC solution to prepare a 3mg / mL drug solution.

[0326] 3. Modeling Scheme

[0327] (1) Purchase 40 6-8 week old C57BL / 6 mice, acclimatize them for one week in an SPF-grade animal room, and divide them into 4 groups: blank, model, berberine, and berberine-5.

[0328] (2) The control group was given 0.2 ml of 0.9% NaCl aqueous solution by gavage. The blank, model, berberine, and berberine-5 groups were given 400 μl of 75 mg / mL Ranitidine intraperitoneally. Half an hour later, each group was given 0.2 ml of 50 mg / mL MNNG by gavage. The administration was carried out daily for 2 weeks.

[0329] (3) One mouse from each of the four groups (blank, model, berberine, and berberine-5) was euthanized and its stomach tissue was collected, fixed, and subjected to pathological examination to analyze whether the CAG model was successfully constructed.

[0330] (4) After successful establishment of the CAG model, 0.2 ml of blank 0.9% NaCl aqueous solution was administered by gavage. The model group was administered 0.2 ml of 10 mg / mL CMC by gavage. The berberine group and berberine-5 group were administered 0.2 ml of 3 mg / mL berberine solution by gavage, and 0.2 ml of 3 mg / mL berberine-5 solution by gavage. The administration was carried out daily for 4 weeks.

[0331] (5) After administration, blood was collected from the eyeballs of mice. Stomach tissue was collected from mice, and after emptying the contents, half of the stomach tissue was used for Western blotting and the other half was fixed for pathological examination.

[0332] The gastric mucosa becomes rough and uneven due to chronic inflammation, resulting in cell atrophy, reduced cell numbers, and proliferation of epithelial cells and glands, sometimes exhibiting a nodular or scaly appearance. As shown in Figure 3, the gastric mucosa of the model group mice exhibited the same condition (unsmooth or peeling-like changes in the gastric mucosa, atrophy of intrinsic glands). In contrast, the berberine and berberine-5 groups, especially the berberine-5 group, showed redder color and a smoother mucosa shape after drug treatment, with the gastric mucosa approaching normal condition. The gastric mucosa in the berberine derivative treatment group was superior to that in the berberine treatment group.

[0333] HE staining was performed on the gastric mucosa of mice in the normal group, model group, berberine group, and berberine-5 group. The results, shown in Figure 4, indicate that compared to the control group, the model group showed a decrease in the number and size of glands, with some areas showing almost no obvious glandular structure. With glandular atrophy, the gastric mucosa becomes thinner. Under HE staining, the thickness of the mucosal layer was significantly less than that of normal gastric mucosa. Chronic atrophic gastritis is usually accompanied by chronic inflammation; HE staining revealed infiltration of lymphocytes and plasma cells in the mucosal and submucosa, indicating successful model establishment. The presence of these inflammatory cells is a response of the gastric mucosa to long-term inflammatory stimulation. In some cases of chronic atrophic gastritis, the gastric mucosal epithelium can be replaced by intestinal epithelial cells, a phenomenon known as intestinal metaplasia. Berberine and berberine-5 groups, especially berberine-5 group, after drug treatment, showed reduced atrophy of gastric mucosal epithelial cells, reduced gland loss, and glands tending to return to normal. The infiltration of lymphocytes and plasma cells was reduced. Berberine-5 is one of the berberine derivatives in this application. Berberine-5 has a therapeutic effect on CAG. Among them, the berberine derivative treatment group showed a better effect in reducing inflammatory infiltration than the berberine treatment group.

[0334] IHC was performed on the gastric mucosa of mice in the blank group, model group, berberine group, and berberine-5 group, respectively. The results are shown in Figure 5. The model group also showed significant increases in inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). These inflammatory mediators promote the inflammatory response by activating nuclear factor-κB (NF-κB), further exacerbating gastric mucosal damage and atrophy. However, in the berberine and berberine derivative groups, the expression levels of inflammatory factors TNF-α, IL-6, and IL-1β decreased, with the decrease in inflammatory factor expression being more pronounced in the berberine derivative treatment group than in the berberine treatment group.

[0335] The results of Western blot analysis are shown in Figure 6. The model group showed a significant increase in the expression levels of inflammatory mediators such as TNF-α, IL-6, and IL-1β proteins. However, in the berberine and berberine-5 groups, the expression levels of TNF-α, IL-6, and IL-1β proteins decreased. The berberine derivative treatment group showed a greater decrease in the expression levels of inflammatory factor proteins than the berberine treatment group.

[0336] The above description is merely a preferred embodiment of this application, but the scope of protection of this application is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in this application, based on the technical solution and application concept of this application, should be included within the scope of protection of this application.

Claims

1. A compound, said compound being a compound of general formula (I) or a pharmaceutically acceptable salt of a compound of general formula (I): R1 is selected from -(CH2) m R3、-(CH2) n -CN, unsubstituted C2-C 10 Alkenyl, unsubstituted C2-C 10 Alkyne group, unsubstituted or via at least one R a Replacement C1-C 10 Alkyl group; m = 1, n = 1–5; R2 is selected from -(CH2). m R3、-(CH2) n -CN, unsubstituted C2-C 10 Alkenyl, unsubstituted C2-C 10 Alkyne group, unsubstituted or via at least one R a Replacement C1-C 10 Alkyl group; m = 1, n = 1–5; R3 is unsubstituted or via at least one R b Substituted phenyl; R a It is -NH2; R b Selected from -NO2, halogen, C1 alkoxy, and C1 alkyl.

2. The compound according to claim 1, wherein the compound is selected from one of the following structures:

3. A pharmaceutical composition comprising the compound of claim 1.

4. A pharmaceutical composition comprising the compound of claim 2.

5. Use of the compound of claim 1 in the preparation of a medicament for treating chronic atrophic gastritis.

6. Use of the compound of claim 2 in the preparation of a medicament for treating chronic atrophic gastritis.